Cytek Biosciences, Inc. (CTKB)
Technology · NasdaqGS
Fundamentals
Valuation and ratings
Cytek Biosciences, Inc. trades at USD4.58. We do not hold enough of the inputs to run a discounted cash flow on this company, so we publish no fair value for it rather than a number we would not defend.
About Cytek Biosciences, Inc.
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
CTKB passes 1 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
8 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Israel Englander, MILLENNIUM MANAGEMENT LLC$27.50M · 0.0% of book
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$3.99M · 0.0% of book
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$2.96M · 0.0% of book
- Ken Griffin, CITADEL ADVISORS LLC$2.06M · 0.0% of book
- Paul Tudor Jones, TUDOR INVESTMENT CORP ET AL$1.40M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Which funds own CTKB?
8 of the institutions we track reported a position in CTKB in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
The full research page for CTKB, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.